Cagrilintide — 10 mg

About Cagrilintide

Human randomized trial · Controlled study formulation

What it is studied for

A long-acting amylin analogue studied in satiety and body-weight regulation.

What selected research found

A 2021 phase 2 trial reported greater body-weight reduction than placebo over 26 weeks, with gastrointestinal adverse events.

Evidence limits

Findings from combination studies with semaglutide cannot be attributed to cagrilintide alone. Clinical evidence does not validate this catalog material for human use.

Selected sources

1. Lau et al., 2021 — Cagrilintide phase 2 trial ↗

References reviewed October 10, 2026.

Research use only. These notes summarize selected publications; they are not a systematic review, medical advice, dosing instructions, or evidence about this product lot. Clinical studies used controlled study formulations and supervision. AuraBio materials are not for human or veterinary use. Review the exact material identity and available lot documentation for your laboratory application.